Catalina Voinescu, MD
Nephrology · Santa Fe, NMNPI 1740387760
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,550 of the $40,956 with a category attached, or 79.5%. Fresenius USA Marketing, Inc. accounts for 81.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $19,046 and has fallen 78.2% since, to $4,145 in 2025. Among nephrology clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $211.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$33K
- Fresenius USA Manufacturing, Inc.$3K
- AstraZeneca$681
- Vifor Pharma, Inc.$510
- Bayer$470
- Amgen$467
- plus $2K from 19 others
Across 269 payments — averaging $374.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$101K
What the payments were for
- Consulting fees$1,0002%
- Speaking & faculty fees$32,55079%
- Travel & lodging$1,7444%
- Food & beverage$5,64714%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 49 | $33,415 |
| Fresenius USA Manufacturing, Inc. | 3 | $3,300 |
| AstraZeneca(2 entities) | 26 | $681 |
| Vifor Pharma, Inc. | 16 | $510 |
| Bayer | 22 | $470 |
| Amgen | 14 | $467 |
| Aurinia Pharma U.S., Inc. | 9 | $389 |
| Ardelyx, Inc. | 7 | $292 |
| Travere Therapeutics, Inc. | 7 | $235 |
| Mallinckrodt Hospital Products Inc. | 6 | $215 |
| Calliditas Therapeutics US Inc. | 4 | $179 |
| GSK | 5 | $176 |
| Otsuka America Pharmaceutical, Inc. | 8 | $166 |
| Baxter Healthcare | 1 | $120 |
| Boehringer Ingelheim | 5 | $91 |
| Novartis | 2 | $42 |
| Nxstage Medical, Inc. | 2 | $37 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Outset Medical Inc | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Velphoro$1,100
- LUPKYNIS$239
- XPHOZAH 30 MG$126
- LOKELMA$125
- Veltassa$125
- Renal - PD$120
- TARPEYO$117
- Tavneos$117
- TERLIVAZ$117
- Kerendia$104
How this compares
$40,956 in reported general payments places this provider in the 95th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 115 | $85,446 |
| XifaxanRifaximin | 13 | $48,665 |
| Sevelamer Carbonate | 186 | $40,986 |
| RenvelaSevelamer Carbonate | 14 | $23,705 |
| KerendiaFinerenone | 34 | $21,402 |
| Cinacalcet Hcl | 51 | $18,819 |
| VelphoroSucroferric Oxyhydroxide | 11 | $17,378 |
| Lanthanum Carbonate | 23 | $15,300 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $13,870 |
| ProcritEpoetin Alfa | 13 | $9,530 |
| JardianceEmpagliflozin | 11 | $6,932 |
| Losartan Potassium | 162 | $2,029 |
| Amlodipine Besylate | 186 | $1,800 |
| Metoprolol Succinate | 71 | $1,357 |
| Lisinopril | 113 | $1,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $681 | $85,446115 claims |
| BayerKerendia | $470 | $21,40234 claims |
| Fresenius USA Marketing, Inc.Velphoro | $33,415 | $17,37811 claims |
| Johnson & JohnsonProcrit | $22 | $9,53013 claims |
| Boehringer IngelheimJardiance | $91 | $6,93211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 nephrology providers in New Mexico.
Other nephrology in Santa Fe
- Tudor OcneanuSanta Fe$6K
- Alexandra VoinescuSanta Fe$4K
- Charnes ChiuSanta Fe$2K
- William Vasquez EspinosaSanta Fe$1K
- Satyaki BanerjeeAlbuquerque$260K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- Jose HenaoLas Cruces$31K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.